Intellectual Property

OCT has developed an extensive library of proprietary compounds. Our IP generation process utilises the latest medical chemistry techniques to develop cannabinoid derivatives and New Chemical Entities that not only harness the therapeutic potential of cannabinoids, but also are simultaneously optimised for efficacy and low toxicity.

These compounds are screened against a number of drug targets across OCT’s research network. Promising hits are taken through a pharma-standard lead optimisation programme and developed to clinical Phase II.

Taken together, these activities generate a large portfolio of Intellectual Property for OCT, which distinguishes the company from other companies working in cannabinoid medication space.